BI-3923948
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BI-3923948, covering 2026-04-15 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) [Phase 1]